Wet AMD, comprising around 10% of the total AMD population, is primarily the target of pharmaceutical companies, representing a market worth billions of dollars. With only two FDA-approved treatments, dry AMD presents a substantial market potential, encompassing approximately 90% of all AMD patients. Key players...
Find MoreLive Coverage of ASCO 2024 Visit Now for Real-Time Insights and Analytical, Impactful Updates!